Evidence-Based Guidelines for the Pharmacologic Management of Methamphetamine Dependence, Relapse Prevention, Chronic Methamphetamine-Related, and Comorbid Psychiatric Disorders in Post-Acute Settings
Abstract
The increasing abuse of the street drug crystal meth (methamphetamine) in many countries worldwide has resulted in a growing demand to treat patients who have acquired a methamphetamine-related disorder. The results of a systematic literature search which led to the consensus-based recommendations by the Working Group of the German Agency for Quality in Medicine (Ärztliches Zentrum für Qualität in der Medizin - ÄZQ) are presented. Pharmacological treatments were reviewed in 58 out of the 103 publications included. They were mainly randomized controlled trials (RCT). Despite increased research activities, none of the medications studied demonstrated a convincing and consistent effect on abstinence rates, despite some having an impact on craving and retention rates or symptom control. In addition, as yet there is no sufficient evidence available for dopamine analogue treatment ("substitution") after the initial withdrawal-period. Methamphetamine-related, post-acute persistent or comorbid syndromes such as methamphetamine-associated psychosis (MAP), depressive syndromes, anxiety, and sleep disorders are usually treated in a symptom-oriented manner. Risks of interactions with methamphetamine have to be taken in account when prescribing medications with doubtful efficacy. Further research is warranted.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
One clinical practice guideline, commissioned by the German Federal Ministry of Health and German Medical Association, was included.
“One clinical practice guideline, commissioned by the German Federal Ministry of Health (BMG) and German Medical Association (BÄK), was included [106, 107] (Table 1).”
From Psychosocial and pharmacologic interventions for problematic methamphetamine use: Findings from a scoping review of the literature (2023) · cites this paper as [107]
Cites
Volkow, N. D., Chang, L., Wang, G.-J., Fowler, J. S., Ding, Y.-S., Sedler, M., Logan, J., Franceschi, D., Gatley, J., Hitzemann, R., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.12.2015 · Cited by 916 · see citing works
Major physical and psychological harms of methamphetamine use
DARKE, S., KAYE, S., McKETIN, R., & DUFLOU, J. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801923702 · Cited by 675 · see citing works
Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E., Medhus, S., Tanum, L., & Franck, J. (2012) · BMC Psychiatry · doi:10.1186/1471-244x-12-221 · Cited by 244 · see citing works
Bupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · see citing works
Methamphetamine Abstinence Syndrome: Preliminary Findings
Newton, T. F., Kalechstein, A. D., Duran, S., Vansluis, N., & Ling, W. W. (2004) · American Journal on Addictions · doi:10.1080/10550490490459915 · Cited by 216 · see citing works
Mirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · see citing works
Bupropion Reduces Methamphetamine-Induced Subjective Effects and Cue-Induced Craving
Newton, T. F., Roache, J. D., Garza, R. D. L., FONG, T. W., Wallace, C. L., Li, S.-H., Elkashef, A. M., Chiang, N., & Kahn, R. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300979 · Cited by 163 · see citing works
Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence
SHOPTAW, S. J., Heinzerling, K. G., Rotheram-Fuller, E. J., Steward, T., Wang, J., Swanson, A., Garza, R. D. L., Newton, T., & Ling, W. W. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.03.010 · Cited by 150 · see citing works
SHOPTAW, S. J., Huber, A., Peck, J. A., Yang, X., Liu, J., Dang, J., Roll, J. M., Shapiro, B., Rotheram-Fuller, E. J., & Ling, W. W. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.005 · Cited by 146 · see citing works
Depression Among Methamphetamine Users
Glasner, S. V., Marinelli‐Casey, P., Hillhouse, M. P., Ang, A., Mooney, L. J., & Rawson, R. A. (2009) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e31819db6fe · Cited by 142 · see citing works
Johnson, B. A., Ait‐Daoud, N., Elkashef, A. M., Smith, E. V., Kahn, R., Vocci, F., Li, S.-H., Bloch, D. A., & the Methamphetamine Study Group (2007) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145707007778 · Cited by 131 · see citing works
Longo, M., Wickes, W., Smout, M., Harrison, S., Cahill, S., & White, J. M. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02717.x · Cited by 122 · see citing works
Ghahremani, D. G., Tabibnia, G., Monterosso, J. R., Hellemann, G., Poldrack, R. A., & London, E. D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.233 · Cited by 119 · see citing works
Modafinil for the treatment of methamphetamine dependence
Anderson, A. L., Li, S.-H., Biswas, K., McSherry, F., Holmes, T. H., Iturriaga, E., Kahn, R., Chiang, N., Beresford, T. P., Campbell, J. L., et al. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.007 · Cited by 117 · see citing works
Simon, S. L., Dean, A. C., Cordova, X., Monterosso, J. R., & London, E. D. (2010) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2010.71.335 · Cited by 117 · see citing works
Topiramate for the treatment of methamphetamine addiction: a multi‐center placebo‐controlled trial
Elkashef, A. M., Kahn, R., Yu, E., Iturriaga, E., Li, S., Anderson, A., Chiang, N., Ait‐Daoud, N., Weiss, D., McSherry, F., et al. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03771.x · Cited by 116 · see citing works
[ADHD in adulthood--guidelines based on expert consensus with DGPPN support].
Ebert, D., Krause, J., & Roth-Sackenheim, C. (2003) · PubMed · Cited by 116 · see citing works
Heinzerling, K. G., Swanson, A.-N., Kim, S., Cederblom, L., Moe, A., Ling, W., & Shoptaw, S. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.11.023 · Cited by 105 · see citing works
Galloway, G., Buscemi, R., Coyle, J., Flower, K., Siegrist, J. D., Fiske, L. A., Baggott, M. J., Li, L., Polcin, D. L., Chen, C. A., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.307 · Cited by 103 · see citing works
Heinzerling, K. G., SHOPTAW, S. J., Peck, J. A., Yang, X., Liu, J., Roll, J. M., & Ling, W. W. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.03.019 · Cited by 102 · see citing works
Grant, J., Odlaug, B., & Kim, S.-W. (2010) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2010.06.018 · Cited by 93 · see citing works
Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder
Ling, W. W., Chang, L., Hillhouse, M. P., Ang, A., Striebel, J. M., Jenkins, J., Hernandez, J. C., Olaer, M., Mooney, L. J., Reed, S. W., et al. (2014) · Addiction · doi:10.1111/add.12608 · Cited by 81 · see citing works
Acute Modafinil Effects on Attention and Inhibitory Control in Methamphetamine-Dependent Humans
Dean, A. C., Sevak, R. J., Monterosso, J. R., Hellemann, G., Sugar, C. A., & London, E. D. (2011) · Journal of Studies on Alcohol and Drugs · doi:10.15288/jsad.2011.72.943 · Cited by 79 · see citing works
Ray, L. A., Bujarski, S., Courtney, K. E., Moallem, N. R., Lunny, K. F., Roche, D., Leventhal, A. M., SHOPTAW, S. J., Heinzerling, K. G., London, E. D., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.83 · Cited by 79 · see citing works
Clinical course and outcomes of methamphetamine-dependent adults with psychosis
Glasner, S. V., Mooney, L. J., Marinelli‐Casey, P., Hillhouse, M. P., Ang, A., & Rawson, R. A. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.12.004 · Cited by 76 · see citing works
A placebo‐controlled trial of mirtazapine for the management of methamphetamine withdrawal
CRUICKSHANK, C. C., MONTEBELLO, M. E., DYER, K. R., QUIGLEY, A., BLASZCZYK, J., TOMKINS, S., & SHAND, D. (2008) · Drug and Alcohol Review · doi:10.1080/09595230801935672 · Cited by 74 · see citing works
A controlled trial of imipramine for the treatment of methamphetamine dependence
Galloway, G. P., Newmeyer, J. A., Knapp, T., Stalcup, S. A., & Smith, D. E. (1996) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(96)00154-7 · Cited by 71 · see citing works
Anderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70 · see citing works
Nejtek, V. A., Avila, M., Chen, L.-A., Zielinski, T., Djokovic, M., Podawlitz, A., Kaiser, K., Bae, S., & Rush, A. J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0808 · Cited by 69 · see citing works
Kalechstein, A. D., De La Garza, II, & Newton, T. F. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2010.00052.x · Cited by 67 · see citing works
Coffin, P. O., Santos, G., Das, M., Santos, D., Huffaker, S., Matheson, T., Gasper, J. J., Vittinghoff, E., & Colfax, G. N. (2012) · Addiction · doi:10.1111/add.12073 · Cited by 67 · see citing works
Mousavi, S. G., Sharbafchi, M. R., Salehi, M., Peykanpour, M., Sichani, N. K., & Maracy, M. R. (2015) · PubMed · Cited by 67 · see citing works
Heinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · Addiction · doi:10.1111/add.12636 · Cited by 64 · see citing works
Sim, T., Simon, S. L., Domier, C. P., Richardson, K., Rawson, R. A., & Ling, W. W. (2001) · Journal of Addictive Diseases · doi:10.1300/j069v21n01_07 · Cited by 64 · see citing works
Newton, T. F., Reid, M. S., Garza, R. D. L., Mahoney, J. J., Abad, A., Condos, R., Palamar, J. J., Halkitis, P. N., Mojisak, J., Anderson, A., et al. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708009097 · Cited by 61 · see citing works
McElhiney, M. C., Rabkin, J. G., Rabkin, R., & Nunes, E. V. (2009) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990802342907 · Cited by 61 · cited 1× · see citing works
“A smaller cohort (n = 13) of HIV-positive men showed positive effects on the BDI in the combination of CBT and modafinil for those with higher initial values in the Beck Depression Inventory [59].”
BackgroundBrown, E. S., & Gabrielson, B. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.05.006 · Cited by 58 · see citing works
von Mayrhauser, C., Brecht, M., & Anglin, M. D. (2001) · Journal of Addictive Diseases · doi:10.1300/j069v21n01_05 · Cited by 57 · see citing works
Imipramine for the Treatment of Cocaine and Methamphetamine Dependence
Galloway, G. P., Newmeyer, J. A., Knapp, T., Stalcup, S. A., & Smith, D. E. (1995) · Journal of Addictive Diseases · doi:10.1300/j069v13n04_08 · Cited by 55 · see citing works
Olanzapine Treatment of Methamphetamine Psychosis
Misra, L. K., Kofoed, L., Oesterheld, J. R., & Richards, G. A. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200006000-00023 · Cited by 53 · see citing works
Verachai, V., Rukngan, W., Chawanakrasaesin, K., Nilaban, S., Suwanmajo, S., Thanateerabunjong, R., Kaewkungwal, J., & Kalayasiri, R. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3485-6 · Cited by 52 · see citing works
Rezaei, F., Emami, M., Zahed, S., Morabbi, M.-J., Farahzadi, M., & Akhondzadeh, S. (2015) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/s40199-015-0092-y · Cited by 51 · see citing works
A review of treatment options for co-occurring methamphetamine use disorders and depression
Hellem, T. L., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000058 · Cited by 51 · cited 1× · see citing works
“In 2 RCTs in which up to 300 mg/day bupropion was given over 12 weeks, no alleviation of depression or anxiety symptoms was observed compared to placebo [9, 11, 55, 56].”
BackgroundFarnia, V., Shakeri, J., Tatari, F., Juibari, T. A., Yazdchi, K., Bajoghli, H., Brand, S., Abdoli, N., & Aghaei, A. (2013) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.861843 · Cited by 49 · see citing works
Creatine as a Novel Treatment for Depression in Females Using Methamphetamine: A Pilot Study
Hellem, T. L., Sung, Y.-H., Shi, X.-F., Pett, M. A., Latendresse, G., Morgan, J., Huber, R. S., Kuykendall, D., Lundberg, K. J., & Renshaw, P. F. (2015) · Journal of Dual Diagnosis · doi:10.1080/15504263.2015.1100471 · Cited by 49 · see citing works
Drug-Induced Psychosis Associated with Crystalline Methamphetamine
Dore, G., & Sweeting, M. (2006) · Australasian Psychiatry · doi:10.1080/j.1440-1665.2006.02252.x · Cited by 47 · see citing works
Sulaiman, A. H., Gill, J. S., Said, M. A., Zainal, N. Z., Hussein, H. M., & Ng, C. G. (2012) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2012.667116 · Cited by 47 · see citing works
Leelahanaj, T., Kongsakon, R., & Netrakom, P. (2005) · PubMed · Cited by 45 · see citing works
Brensilver, M., Heinzerling, K. G., Swanson, A., & SHOPTAW, S. J. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.03.027 · Cited by 43 · see citing works
Zorick, T. S., Sugar, C. A., Hellemann, G., SHOPTAW, S. J., & London, E. D. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.04.015 · Cited by 42 · see citing works
Hester, R., Lee, N., Pennay, A., Nielsen, S., & Ferris, J. (2010) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0021791 · Cited by 42 · see citing works
McCann, D. J., & Li, S. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00263.x · Cited by 41 · see citing works
Lee, N., Pennay, A. E., Hester, R., McKetin, R., Nielsen, S., & Ferris, J. (2012) · Drug and Alcohol Review · doi:10.1111/j.1465-3362.2012.00473.x · Cited by 35 · see citing works
An Exploratory Study: The Use of Paroxetine for Methamphetamine Craving
Piasecki, M. P., Steinagel, G. M., Thienhaus, O. J., & Kohlenberg, B. S. (2002) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2002.10399967 · Cited by 35 · see citing works
Double‐blind placebo‐controlled evaluation of the PROMETA™ protocol for methamphetamine dependence
Ling, W. W., SHOPTAW, S. J., Hillhouse, M. P., Bholat, M. A., Charuvastra, C., Heinzerling, K. G., Chim, D., Annon, J. J., Dowling, P. T., & Doraimani, G. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03619.x · Cited by 35 · see citing works
Ma, J. Z., Johnson, B. A., Yu, E., Weiss, D., McSherry, F., Saadvandi, J., Iturriaga, E., Ait‐Daoud, N., Rawson, R. A., Hrymoc, M., et al. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.10.009 · Cited by 32 · see citing works
Muld, B. B., Jokinen, J., Bölte, S., & Hirvikoski, T. (2014) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2014.11.005 · Cited by 32 · see citing works
Wang, G., Zhang, Y., Zhang, S., Chen, H., Xu, Z., Schottenfeld, R. S., Hao, W., & Chawarski, M. C. (2015) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2015.11.009 · Cited by 32 · see citing works
Obermeit, L. C., Cattie, J. E., Bolden, K. A., Marquine, M. J., Morgan, E. E., Franklin, D. R., Atkinson, J. H., Grant, I., & Woods, S. P. (2013) · Addictive Behaviors · doi:10.1016/j.addbeh.2013.08.010 · Cited by 31 · see citing works
Salo, R. E., Fassbender, C., Iosif, A., Ursu, S., Leamon, M. H., & Carter, C. (2013) · Psychiatry Research · doi:10.1016/j.psychres.2013.06.030 · Cited by 30 · see citing works
Wang, L., Lin, S., Chen, Y., Huang, M., Chen, T., Ree, S., & Chen, C. (2016) · Psychopathology · doi:10.1159/000445065 · Cited by 28 · see citing works
Verrico, C. D., Mahoney, J. J., Thompson-Lake, D. G. Y., Bennett, R. S., Newton, T. F., & Garza, R. D. L. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571300134x · Cited by 26 · see citing works
Open Trial of Injectable Risperidone for Methamphetamine Dependence
Meredith, C. W., Jaffe, C., Cherrier, M. M., Robinson, J. P., Malte, C. A., Yanasak, E. V., Kennedy, A., Ferguson, L. C., Tapp, A. M., & Saxon, A. J. (2009) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31818e2185 · Cited by 23 · see citing works
Urschel, H. C., Hanselka, L. L., & Baron, M. I. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109349837 · Cited by 23 · see citing works
Barkla, X. M., McArdle, P., & Newbury‐Birch, D. (2015) · BMC Psychiatry · doi:10.1186/s12888-015-0657-9 · Cited by 22 · see citing works
Kalechstein, A. D., Mahoney, J. J., Verrico, C. D., & Garza, R. D. L. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.045 · Cited by 17 · see citing works
Treating Methamphetamine-Induced Resistant Psychosis with Clozapine
Seddigh, R., Keshavarz‐Akhlaghi, A., & Shariati, B. (2014) · Case Reports in Psychiatry · doi:10.1155/2014/845145 · Cited by 13 · see citing works
Donepezil in a chronic drug user—a potential treatment?
Jovanovski, D., & Zakzanis, K. K. (2003) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.530 · Cited by 6 · see citing works
When the Evidence is not Enough: Commentary on Härtel-Petri et al.
McKetin, R., & ALLSOP, S. J. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-102184 · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Fregni, F., El-Hagrassy, M. M., Pacheco‐Barrios, K., Carvalho, S., Leite, J., Simis, M., Brunelin, J., Nakamura-Palacios, E. M., Marangolo, P., Venkatasubramanian, G., et al. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa051 · Cited by 617 · see citing works
Neurobiology, Clinical Presentation, and Treatment of Methamphetamine Use Disorder: A Review
Paulus, M. P., & Stewart, J. L. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.0246 · Cited by 310 · see citing works
Winkelman, T. N. A., Admon, L. K., Jennings, L., Shippee, N. D., Richardson, C. R., & Bart, G. B. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3758 · Cited by 156 · see citing works
Hoots, B., Vivolo-Kantor, A. M., & Seth, P. (2020) · Addiction · doi:10.1111/add.14878 · Cited by 150 · see citing works
Ru, Q., Xiong, Q., Zhou, M., Chen, L., Tian, X., Xiao, H., Li, Z., & Li, Y. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.11.072 · Cited by 57 · see citing works
Acheson, L. S., Williams, B. H., Farrell, M., McKetin, R., Ezard, N., & Siefried, K. J. (2022) · Drug and Alcohol Review · doi:10.1111/dar.13511 · Cited by 45 · see citing works
Xu, X., Ding, X., Chen, L., Chen, T., Su, H., Li, X., Ye, Y., Shi, W., Ji, J., Zhao, M., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.056 · Cited by 39 · see citing works
Gan, H., Zhao, Y., Jiang, H., Zhu, Y., Chen, T., Tan, H., Zhong, N., Du, J., & Zhao, M. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00551 · Cited by 27 · see citing works
Goofballing of Opioid and Methamphetamine: The Science Behind the Deadly Cocktail
Hazani, H. M., Mohamed, I. N., Mustapha, M., Mohamed, W. M. Y., Yahaya, M. F., Teoh, S. L., Mohamed, R. M. P., Isa, M. F. M., Abdulrahman, S. M., Ramadah, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.859563 · Cited by 25 · see citing works
Hakami, T. M., Mahmoud, M., Mohammed, B., & El‐Setouhy, M. (2021) · Eastern Mediterranean Health Journal · doi:10.26719/emhj.21.003 · Cited by 25 · see citing works
Xu, X., Pan, J., Li, X., Cui, Y., Mao, Z., Wu, B., Xu, H., Zhou, W., & Liu, Y. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.118.255729 · Cited by 24 · see citing works
Yang, M., Yang, C.-Q., Liu, T., & London, E. D. (2019) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2019.1676451 · Cited by 22 · see citing works
Amphetamine Related Psychiatric Disorders
Mullen, J. M., Richards, J. R., & Crawford, A. (2019) · StatPearls · Cited by 21 · see citing works
Wang, X., Tong, B., Hui, R., Hou, C., Zhang, Z., Zhang, L., Xie, B., Ni, Z., Cong, B., Ma, C., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.808807 · Cited by 20 · see citing works
Frost, M. C., Williams, E. C., Kingston, S., & Banta‐Green, C. J. (2018) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000426 · Cited by 19 · see citing works
Wang, Y., Wang, M., Xie, B., Wen, D., Li, W., Zhou, M., Wang, X., Lu, Y., Cong, B., Ni, Z., et al. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.12.003 · Cited by 18 · see citing works
Substance-Related and Addictive Disorders
(2022) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425787.x16_substance_related_disorders · Cited by 20 · see citing works
Wu, M., Satogami, K., Liang, C., Stubbs, B., Carvalho, A. F., Brunoni, A. R., Su, K., Tu, Y., Wu, Y., Chen, T., et al. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13452 · Cited by 17 · see citing works
Madden, J. T., Reyna, N. C., & Pentkowski, N. S. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.108178 · Cited by 16 · see citing works
Oladapo, A., Kannan, M., Deshetty, U. M., Singh, S., Buch, S. J., & Periyasamy, P. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103517 · Cited by 14 · see citing works
Update on methamphetamine: an old problem that we have recently encountered
Evren, C., & Bozkurt, M. (2018) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.5350/dajpn20183101001 · Cited by 14 · see citing works
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13 · see citing works
Xu, X., Fan, R., Ruan, Y., Xu, M., He, J., Cao, M., Li, X., Zhou, W., & Liu, Y. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.111970 · Cited by 13 · see citing works
Chen, Y.-H., Yang, J., Wu, H., Beier, K. T., & Sawan, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1085036 · Cited by 13 · see citing works
Kamp, F., Hager, L., Proebstl, L., Schreiber, A., Riebschläger, M., Neumann, S., Straif, M., Schacht-Jablonowsky, M., Falkai, P., Pogarell, O. M., et al. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.05.029 · Cited by 9 · see citing works
Leidl, D. M., Takhar, P., & Li, H. (2023) · International Journal of Mental Health Nursing · doi:10.1111/inm.13144 · Cited by 9 · see citing works
Management of withdrawal from alcohol and other drugs
Lintzeris, N., Sunjic, S., Demirkol, A., Branezac, M., Ezard, N., Siefried, K. J., Acheson, L. S., Bascombe, F., Tremonti, C., & Haber, P. (2019) · doi:10.57022/mjjp9930 · Cited by 9 · see citing works
Nickel, N. C., Enns, J. E., Freier, A., McCulloch, S., Chartier, M., Casidsid, H. J. M., Balogun, O. D., Mulhall, D., Drăgan, R., Sarkar, J., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062127 · Cited by 6 · see citing works
Acheson, L. S., Ezard, N., Lintzeris, N., Dunlop, A. J., Brett, J., Rodgers, C., Gill, A., Christmass, M. A., McKetin, R., Farrell, M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0275371 · Cited by 5 · see citing works
Comparing Methamphetamine-Induced Psychosis With Positive and Cognitive Symptoms of Schizophrenia
Uludağ, K., Jadhav, A., & Kara, F. (2024) · Advances in bioinformatics and biomedical engineering book series · doi:10.4018/979-8-3693-4439-2.ch007 · Cited by 2 · see citing works
Methamphetamine-Induced Psychosis
Crockford, D. N., Meunier, S., & Ghosh, S. M. (2019) · The Canadian Journal of Addiction · doi:10.1097/cxa.0000000000000068 · Cited by 2 · see citing works
When the Evidence is not Enough: Commentary on Härtel-Petri et al.
McKetin, R., & ALLSOP, S. J. (2017) · Pharmacopsychiatry · doi:10.1055/s-0043-102184 · Cited by 1 · see citing works
Characteristics of Amphetamine Psychosis with Respect to the Length of Drug Exposure
Sokolova, I. M., Babina, A., & Vysotskyi, M. M. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220726141936 · Cited by 1 · see citing works
Pharmacodynamic Evaluation: Drug Dependency and Addiction
Tenev, V., & Nikolova, M. G. (2020) · Springer eBooks · doi:10.1007/978-3-319-68864-0_49
Pharmacodynamic Evaluation: Drug Dependency and Addiction
Tenev, V., & Nikolova, M. G. (2018) · Springer eBooks · doi:10.1007/978-3-319-56637-5_49-1
Fung, S. S.-P., & Lee, A. (2023) · Drugs & Therapy Perspectives · doi:10.1007/s40267-023-00983-5
Agrawal, A., Scardino, B., Xing, D. G., Bhuiyan, M. S., Bevins, R. A., Modi, K. A., Helmy, T. A., Conrad, S. A., Goeders, N. E., Bhuiyan, M. M. R., et al. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1566481
Insomnia is associated with psychological distress in individuals with methamphetamine dependence
Matepi, Q. G. J., Clifford, B., Acheson, L. S., McKetin, R., Montebello, M. E., Siefried, K. J., Chan, D. K. E., Olsen, N., May, R., & Ezard, N. (2025) · Australasian Psychiatry · doi:10.1177/10398562251406035
Asadolah‐poor‐kashi, M. Z., Banafshe, H. R., Simani, M., Ghoreishi, F. S., Zanjani, Z., & Ghaderi, A. (2026) · Jundishapur Journal of Natural Pharmaceutical Products · doi:10.5812/jjnpp-172452
- Authors
- Härtel-Petri, R., Krampe-Scheidler, A., Braunwarth, W.-D., Havemann-Reinecke, U., Jeschke, P., Looser, W., Mühlig, S., Schäfer, I., Scherbaum, N., Bothe, L., Schaefer, C., & Hamdorf, W.
- Affiliations
- Practice for Psychiatry and Psychotherapy, Luitpoldplatz 10, Bayreuth
- German Agency for Quality in Medicine (DE)
- Paracelsus Medizinische Privatuniversität (DE)
- University Medical Center Göttingen, Clinic for Psychiatry and Psychotherapy, Center of Nanoscale Microscopy and Molecular Physiology of the Brain (CNMPB), University of Göttingen, Göttingen
- Joint Neurology Practice, Gesundheitszentrum Silberhöhe e.V., Halle (Saale)
- Department for Addictive Disorders, LVR-Hospital Dueren, Dueren
- Chemnitz University of Technology (DE)
- Universität Hamburg (DE)
- University of Duisburg-Essen (DE)
- AHG Klinik Mecklenburg, Rehna OT Parber
- Venue
- Pharmacopsychiatry
- Publisher
- Georg Thieme Verlag KG
- Published
- 2017-04-26
- Volume
- 50
- Issue
- 03
- Pages
- 96-104
- ISSN
- 0176-3679 (ISSN-L)
- 1439-0795
- OpenAlex
- W2608088535
- Cited by
- 39
- References
- 69
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 1 · 2023: 4 · 2022: 9 · 2021: 2 · 2020: 7 · 2019: 5 · 2018: 6 · 2017: 1
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacopsychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- methamphetamine dependence, crystal methamphetamine, pharmacotherapy, relapse prevention, psychiatric comorbidity, withdrawal time, craving, depressive syndrome, anxiety, sleep disorders, drug interactions, post-acute care, abstinence
- MeSH terms
- Mental Disorders, Benzodiazepines, Humans, Methamphetamine, Psychoses, Substance-Induced, Recurrence, Antipsychotic Agents, Comorbidity, Practice Guidelines as Topic, Evidence-Based Medicine, Amphetamine-Related Disorders, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
